Memantine: What It Does and What It Cannot Do
Memantine is prescribed for Alzheimer’s disease, and the most useful thing to establish at the outset is what it is for. It does not slow the underlying disease, does not restore what has been lost, and is not appropriate for the early stages. What it does is produce a modest improvement in day-to-day functioning at a particular point in the illness.
That sounds like a disappointing summary and it is a realistic one, and families given a realistic account beforehand generally do better with it than families expecting something else.
⚡ What it actually does. Glutamate is the brain’s main excitatory signal. In Alzheimer’s disease the receptors it acts on become persistently over-stimulated, and sustained excess calcium entry through them damages neurons — a process called excitotoxicity. Memantine blocks that receptor in an unusual way: it sits loosely enough to be displaced by a genuine signal, while blocking the constant low-level background stimulation that does the damage. That is why it dampens the harmful noise without silencing the useful message, and it is why it is tolerated as well as it is.
One correction worth making, because it appears widely including in earlier versions of this article: memantine is not an amyloid drug and does not work by reducing oxidative stress associated with amyloid. It acts on glutamate signalling. The distinction matters because it explains both what to expect and where it does not work.
🎯 Who it is for
Memantine is licensed for moderate to severe Alzheimer’s disease, and that limit is meaningful rather than administrative.
In mild disease, trials have not shown a worthwhile benefit. The other class of dementia medicines — the cholinesterase inhibitors — occupies that stage instead. Prescribing memantine in mild Alzheimer’s exposes someone to side effects for very little in return, and it is one of the more common misapplications of the drug.
| Cholinesterase inhibitors | Memantine | |
|---|---|---|
| Examples | Donepezil, rivastigmine, galantamine | Memantine |
| Acts on | Acetylcholine — raises levels by slowing its breakdown | Glutamate — dampens excessive receptor stimulation |
| Stage | Mild to moderate | Moderate to severe |
| Common side effects | Nausea, diarrhoea, poor appetite, vivid dreams, slow pulse, cramps | Dizziness, headache, constipation, confusion |
| Tolerability | Gastrointestinal effects are the usual reason for stopping | Generally better tolerated |
| Heart | Can slow the heart rate; caution with conduction problems | No comparable effect |
The two classes act on entirely different systems, which is why they can be combined. In moderate to severe disease, memantine added to a cholinesterase inhibitor is a recognised approach, with some evidence of additional benefit over either alone. Guidelines differ on how strongly to recommend it, and the practical question is usually whether the person is tolerating both.
📉 What benefit actually looks like
This is the section families most need and least often get, because the expectation set at the start determines whether the treatment is judged fairly.
Alzheimer’s disease progresses. A medicine that produces a modest improvement in a progressive illness rarely results in someone visibly getting better. More often it looks like a period of stability, or a slower rate of decline, which is far harder to perceive from the inside.
A family watching closely, day to day, is comparing today with yesterday and sees no improvement. The relevant comparison is with where the person would have been without it, which nobody can observe.
Two practical consequences follow.
Define what you are watching for before starting. Specific, observable things: managing to dress without help, recognising visitors, being less agitated in the late afternoon, sleeping through the night, needing less prompting at meals. Written down, with a date. Impressions three months later are unreliable; a list is not.
Judge over months rather than weeks. A four-week build-up is required before the full dose is even reached, and a fair assessment takes around three months from starting.
💡 The most useful question to ask a doctor at the start is what would count as this working. If the answer is vague, benefit cannot be assessed later and the drug tends to continue by default. If the answer is specific — less agitation in the evenings, fewer prompts needed for washing, better recognition of family — then in three months there is something to check it against. That single question improves how this medicine is used more than anything else in this article.
🪜 The four-week build-up
Memantine is started low and increased weekly, and the schedule is not optional caution.
The usual pattern is 5 mg daily in the first week, 10 mg in the second, 15 mg in the third and 20 mg from the fourth, which is the maintenance dose. Higher strengths are given as a divided dose or as a once-daily preparation depending on the form.
Starting at the full dose causes dizziness, confusion and unsteadiness — effects that in an older person with dementia are both distressing and dangerous, since falls are a major cause of harm in this group. Building up gradually largely avoids them.
The practical implications are that nothing much will be noticeable for the first month, and that a missed period of several days means restarting the build-up rather than resuming at the top dose.
🫀 Kidneys, which determine the dose
Memantine is removed from the body largely unchanged by the kidneys rather than broken down by the liver, and that single fact drives most of its practical prescribing.
Reduced kidney function means a reduced dose. In moderate impairment the maintenance dose is typically halved, and in severe impairment it is used with considerable caution or avoided. Since kidney function declines with age and the people taking this drug are mostly elderly, it should be measured before starting and rechecked periodically rather than assumed.
Anything that makes the urine less acidic raises memantine levels, because the drug is excreted more slowly. That includes sodium bicarbonate taken for indigestion, certain diuretics used in glaucoma, and some other medicines and dietary changes. It is an unusual interaction and worth mentioning, since bicarbonate is bought without a prescription.
Dehydration, vomiting or diarrhoea reduce kidney clearance and can raise levels enough to cause confusion — which then gets attributed to the dementia rather than to the illness that caused it.
⚠️ Side effects, in proportion
Memantine is generally well tolerated, and the earlier version of this article listed its effects without indicating how often each occurs, which makes any drug look alarming.
Reasonably common: dizziness, headache, constipation, drowsiness, and a rise in blood pressure. Most appear during the build-up and settle.
Less common: confusion, hallucinations, vomiting, unsteadiness, and abnormal gait.
Uncommon or rare: seizures, blood clots, inflammation of the pancreas, psychotic reactions, and heart failure.
Two of these deserve comment. Confusion and hallucinations are the awkward ones, because they are also features of the illness being treated — which is precisely why the timing matters. A clear worsening in the days after starting or increasing the dose points toward the drug; a gradual change over months points toward progression.
And blood pressure is worth checking after starting, since a rise is not something anyone thinks to look for with a dementia medicine.
🚫 Where it does not work
Memantine is a treatment for Alzheimer’s disease, and dementia is not one condition.
Frontotemporal dementia. Trials have been negative, and there has been some suggestion of worsening. It is not recommended.
Vascular dementia. Evidence is weak and inconsistent, and it is not licensed for it. Managing blood pressure, cholesterol, diabetes and smoking does more here than any dementia drug.
Dementia with Lewy bodies. Cholinesterase inhibitors are generally preferred, and they often work notably well in this form. Memantine has some supporting evidence and is a secondary option.
🔴 One warning belongs here regardless of which drug is being used. In dementia with Lewy bodies, antipsychotic medicines can provoke a severe reaction — marked worsening of movement, rigidity, drowsiness, and occasionally a life-threatening deterioration. Since these drugs are frequently given for agitation or hallucinations, and hallucinations are a core feature of this form of dementia, the situation arises readily. Anyone with dementia who has visual hallucinations, marked fluctuation in alertness, or parkinsonian features should have this flagged before any antipsychotic is started.
💊 The drugs that undo it quietly
This section is worth more than the rest of the article for many people, because reviewing what someone is already taking frequently produces a larger improvement than adding memantine does.
A large group of common medicines block acetylcholine — the same chemical that cholinesterase inhibitors are prescribed to preserve. Their effects on memory, attention and confusion accumulate, and long-term use has been associated with increased dementia risk in observational studies.
| Medicine group | Commonly taken for |
|---|---|
| Bladder antispasmodics | Urinary urgency and incontinence. Among the strongest offenders, and very widely prescribed in this age group |
| Older sedating antihistamines | Allergy, and frequently bought over the counter as sleep aids |
| Tricyclic antidepressants | Depression, nerve pain, sleep |
| Some antipsychotics and antiemetics | Agitation, nausea, dizziness |
| Some antispasmodics for the gut | Abdominal cramping |
Alongside these, benzodiazepines and sleeping tablets worsen confusion and substantially increase falls, and opioid painkillers add to the same picture.
The practical step is a full medication review with someone competent to do it — every prescription plus everything bought over the counter. Stopping or substituting one or two of these can produce a clearer improvement than anything added, and it costs nothing.
🛑 When to stop
An uncomfortable subject, usually avoided, and better handled deliberately than by drift.
Reasons to review whether to continue: no discernible benefit after an adequate trial at full dose; side effects outweighing benefit; disease progression to a point where the goals the treatment was aiming at no longer apply; or difficulty taking tablets making administration distressing.
Two points about how to do it. Some people deteriorate noticeably when it is withdrawn, which is itself informative — it can reveal a benefit that was not apparent while it was being taken. And stopping should be gradual and monitored, with the option of restarting if a clear decline follows.
Continuing a medicine indefinitely because nobody wants to raise the question is not a decision, and the question is a legitimate one to ask rather than one to feel guilty about.
🏠 What matters alongside the medication
The effects here are frequently larger than the drug’s, and they receive a fraction of the attention.
Hearing. Untreated hearing loss impairs communication, accelerates withdrawal and worsens apparent cognitive function. A hearing aid is one of the highest-value interventions in this whole area and is routinely neglected.
Vision. Cataracts and uncorrected sight problems worsen disorientation and hallucinations.
Pain. Untreated pain in someone unable to report it is a leading cause of agitation, and agitation is then treated with sedatives. Anyone newly agitated should be examined for pain, constipation and urinary retention before anything is prescribed for behaviour.
Infection. A sudden marked worsening over hours or days is delirium until proven otherwise, not progression. It has a cause, usually a treatable one, and it needs same-day assessment.
Depression, which is common, treatable, and easily mistaken for worsening dementia.
Routine, light and activity. Consistent daily structure, daylight exposure and physical activity all reduce confusion and improve sleep, and evening confusion in particular responds to good lighting.
📌 About the other uses
Memantine appears occasionally in other contexts — as an addition in obsessive compulsive disorder, in some nerve pain conditions, and in attention difficulties.
All of these are off-label, meaning outside its approved indications, and the evidence behind them is limited and inconsistent. Off-label prescribing is legitimate and common, and it is worth knowing which category you are in, because the confidence attached to a use in moderate to severe Alzheimer’s is not the same as the confidence attached to these.
🩺 When to seek advice
- Sudden worsening over hours or days — delirium, not progression. Same-day assessment
- New or worsening confusion after starting or increasing the dose
- Falls, dizziness or unsteadiness
- New hallucinations, particularly before any antipsychotic is considered
- Vomiting, diarrhoea or poor fluid intake, which can raise drug levels
- A seizure, at any point
- New agitation — check for pain, constipation and infection first
- No apparent benefit three months after reaching the full dose
- Before starting any new medicine, including anything bought over the counter
- Carer exhaustion, which is a clinical issue rather than a personal failing
Treatment is stocked in the Alzheimers and dementia category, including Namenda (memantine 10 mg), and the cholinesterase inhibitors Aricept (donepezil) and Exelon (rivastigmine). Which is appropriate depends on the type of dementia, the stage, kidney function and what else is being taken.
❓ Frequently asked questions
Does memantine slow Alzheimers disease?
No. It produces a modest improvement in day-to-day functioning and does not alter the underlying disease process or restore what has been lost. That is a realistic account rather than a dismissive one, and families given it beforehand generally do better with the treatment than those expecting something different.
How does it actually work?
Glutamate is the brain's main excitatory signal, and in Alzheimer's disease its receptors become persistently over-stimulated, allowing excess calcium in and damaging neurons. Memantine blocks that receptor loosely enough to be displaced by a genuine signal while blocking the constant background stimulation that does the damage. It is not an amyloid drug and does not work through antioxidant effects.
Why is it not used in early Alzheimers?
Because trials in mild disease have not shown a worthwhile benefit. It is licensed for moderate to severe Alzheimer's, and the cholinesterase inhibitors occupy the earlier stage instead. Prescribing memantine in mild disease exposes someone to side effects for very little in return, and it is one of the commoner misapplications of the drug.
How will we know whether it is working?
Define specific observable things before starting, written down with a date — dressing without help, recognising visitors, less agitation in the late afternoon, fewer prompts at meals. In a progressive illness, benefit often looks like stability or slower decline rather than improvement, which is very hard to perceive day to day. Judge at around three months, since the build-up alone takes four weeks.
Why does the dose increase so slowly?
Because starting at the full dose causes dizziness, confusion and unsteadiness, which in an older person with dementia is both distressing and dangerous given the risk of falls. Building up over four weeks largely avoids that. It also means little will be noticeable in the first month, and that after several missed days the build-up is restarted rather than resumed at the top dose.
Do the kidneys matter with this drug?
They determine the dose. Memantine is removed largely unchanged by the kidneys, so reduced function means a reduced dose — typically halved in moderate impairment and used cautiously or avoided in severe. Kidney function declines with age, so it should be measured before starting and rechecked. Dehydration, vomiting or diarrhoea can raise levels enough to cause confusion.
Can it be taken with donepezil?
Yes. The two act on entirely different systems — one on acetylcholine, the other on glutamate — so they can be combined. In moderate to severe disease, adding memantine to a cholinesterase inhibitor is a recognised approach with some evidence of additional benefit over either alone. Guidelines vary in how strongly they recommend it, and tolerability of both is the practical question.
Which medicines make dementia worse?
A large group that blocks acetylcholine — bladder antispasmodics for urinary urgency, older sedating antihistamines including those bought as sleep aids, tricyclic antidepressants, some antipsychotics and antiemetics, and some gut antispasmodics. Benzodiazepines, sleeping tablets and opioids add confusion and falls. A full medication review often produces more improvement than anything added.
He has suddenly become much worse. Is the dementia progressing?
A marked worsening over hours or days is delirium until proven otherwise, not progression, and it needs same-day assessment. Dementia declines over months, not overnight. The usual causes are infection, pain, constipation, urinary retention, dehydration or a new medicine, and most are treatable. Anyone newly agitated should be checked for those before anything is prescribed for behaviour.
When should we consider stopping it?
Where there is no discernible benefit after an adequate trial at full dose, where side effects outweigh benefit, where the disease has progressed past the goals the treatment aimed at, or where taking tablets has become distressing. Stopping should be gradual and monitored, since some people decline noticeably on withdrawal — which itself reveals a benefit that was not apparent while it was being taken.
📑 Sources and editorial
- FDA and EMA prescribing information for memantine, including renal dosing and urinary pH effects
- NICE guidance on donepezil, galantamine, rivastigmine and memantine for Alzheimers disease
- Cochrane reviews of memantine for dementia
- Trials of memantine added to cholinesterase inhibitor therapy in moderate to severe disease
- Trials of memantine in frontotemporal dementia and in vascular dementia
- Literature on antipsychotic sensitivity in dementia with Lewy bodies
- Research on cumulative anticholinergic burden, cognition and dementia risk
- Guidance on the recognition and management of delirium superimposed on dementia
- Evidence on hearing loss, sensory impairment and cognitive function
- Related products: Alzheimers and dementia category
- RXshop Editorial Team — reviewed by James Carter, MD, Neurologist
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.